Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cowealth Medical China CoSHSE:603122 +9.98%44 Return-on-Tangible-Asset is 0.22% as of Jun. 2026, which is 97% below its 10-year median of 6.48. GuruFocus rates SHSE:603122 with a GF Score™ of 44/100 and a GF Value™ of ¥4.40 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Cowealth Medical China Co ranks worse than 52.58% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cowealth Medical China Co's annualizedNet Income for the quarter that ended in Jun. 2026 was ¥3.1 Mil. Cowealth Medical China Co's average total tangible assets for the quarter that ended in Jun. 2026 was ¥1,412.7 Mil. Therefore, Cowealth Medical China Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 0.22%.
The historical rank and industry rank for Cowealth Medical China Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:603122'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.31 Med: 6.48 Max: 9.9
Current: -2.3
During the past 9 years, Cowealth Medical China Co's highest Return-on-Tangible-Asset was 9.90%. The lowest was -2.31%. And the median was 6.48%.
SHSE:603122's Return-on-Tangible-Asset is ranked worse than 52.58% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.78
vs SHSE:603122: -2.30
Cowealth Medical China Co (SHSE:603122) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Cowealth Medical China Co Return-on-Tangible-Asset Related Terms
Cowealth Medical China Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Cowealth Medical China Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical China Co Return-on-Tangible-Asset Chart
SHSE:603122 vs TMO, DHR, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Cowealth Medical China Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical China Co Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cowealth Medical China Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Cowealth Medical China Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.22% mean?
Cowealth Medical China Co (SHSE:603122) has a Return-on-Tangible-Asset of 0.22% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cowealth Medical China Co and its competitors. This is 97% below median its historical median of 6.48. According to the industry distribution chart, Cowealth Medical China Co ranks #112 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Cowealth Medical China Co's Return-on-Tangible-Asset too high?
Cowealth Medical China Co's current Return-on-Tangible-Asset of 0.22% is 97% below median its 10-year median of 6.48. Based on the distribution chart, Cowealth Medical China Co ranks #112 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cowealth Medical China Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cowealth Medical China Co ranks #112 out of 213 companies for Return-on-Tangible-Asset. This places Cowealth Medical China Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cowealth Medical China Co and its competitors. Cowealth Medical China Co's current Return-on-Tangible-Asset is 0.22%, which is 97% below median its own 10-year median of 6.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.40, compared to a current price of ¥13.56 — trading 208.2% above its estimated fair value. The current Return-on-Tangible-Asset is 0.22%, which is 97% below median its 10-year median of 6.48. Cowealth Medical China Co's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current Return-on-Tangible-Asset is 0.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued.
The current stock price of ¥13.56 is trading 208.2% above its estimated GF Value™ of ¥4.40.
GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.
Key valuation signals for SHSE:603122:
Return-on-Tangible-Asset: 0.22% (97% below median its 10-year median of 6.48)
GF Value™: ¥4.40 vs. price of ¥13.56 (208.2% above fair value)
No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603122 has been successfully added to your 
